Prosecution Insights
Last updated: April 19, 2026
Application No. 18/034,793

CD73 INHIBITOR AND USE THEREOF

Non-Final OA §102§112
Filed
May 01, 2023
Examiner
ISMAIL, REHANA
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Wuhan Humanwell Innovative Drug Research And Development Center Limited Company
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
3y 4m
To Grant
99%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allow Rate
56 granted / 71 resolved
+18.9% vs TC avg
Strong +29% interview lift
Without
With
+29.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
41 currently pending
Career history
112
Total Applications
across all art units

Statute-Specific Performance

§101
4.0%
-36.0% vs TC avg
§103
27.3%
-12.7% vs TC avg
§102
20.0%
-20.0% vs TC avg
§112
25.5%
-14.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 71 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Current Status of 18/034,793 This Office Action is in response to the amended claims of 05/01/2023. Claims 1, 7, 9, and 16 are original; and claims 2-6, 8, 10-12, 17, and 22-23, are currently amended; claims 25-28 are new. Claims 1-12, 16-17, 22-23 and 25-28 are examined in this office action. Priority The effective filing date is 11/05/2021 because claims find support in application PCT/CN2021/129079. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement The information disclosure statement (IDS) submitted on 05/04/2023, 05/09/2023, 08/06/2024 and 12/02/2024. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-12, 16-17, 22-23 and 25-28 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1-4, 7 and 12 recites variable Rb without defining the variable. One of ordinary skill in the art would not be reasonably apprised of the scope of the invention as written thus rendering metes and bound of claims 1-4, 7 and 12 indefinite. Claims 5-11, 16-17, 22-23 and 25-28 also rejected because they refer back to claim but do not remedy the bases for the rejection of claims. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-12 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Dally et.al (WO-2019168744-A1). Dally the synthesis of compound PNG media_image1.png 178 188 media_image1.png Greyscale ( page 20) (examiner is interpreting this as a prodrug of compound of formula I) thus anticipating claims 1-12. Applicant can overcome this rejections by deleting the “prodrug” from the claims 1-12). Conclusion No claims are allowable as written. Please note the difference between compound PNG media_image1.png 178 188 media_image1.png Greyscale and instant clam 1, is that instant claims do not support R1 to be CF2. Therefore, examiner interpreted compound PNG media_image1.png 178 188 media_image1.png Greyscale as prodrug. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rehana Ismail whose telephone number is (703)756-4776. The examiner can normally be reached Monday-Friday 9:00am-5:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew D Kosar can be reached at (571)272-913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /R.I./Examiner, Art Unit 1625 /JOHN S KENYON/Primary Patent Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

May 01, 2023
Application Filed
Aug 15, 2025
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599613
COMPOSITION COMPRISING DUTASTERIDE
2y 5m to grant Granted Apr 14, 2026
Patent 12599555
FORMULATION
2y 5m to grant Granted Apr 14, 2026
Patent 12593844
METHOD AND COMPOUNDS TO INDUCE PLANT TOLERANCE AGAINST ARTHROPOD PESTS
2y 5m to grant Granted Apr 07, 2026
Patent 12595246
CRYSTALLINE AND AMORPHOUS FORMS OF N-(5-((4-ETHYLPIPERAZIN-1-YL)METHYL)PYRIDINE-2-YL)-5-FLUORO-4-(3-ISOPROPYL-2-METHYL-2H-INDAZOL-5-YL)PYRIMIDIN-2-AMINE AND ITS SALTS, AND PREPARATION METHODS AND THERAPEUTIC USES THEREOF
2y 5m to grant Granted Apr 07, 2026
Patent 12577196
QUATERNARY AMINE COMPOUNDS WITH ISOPROPYLMETHYLPHENOL ESTER MOIETIES AS ANTIVIRALS, ANTIBACTERIALS AND ANTIMYCOTICS
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
99%
With Interview (+29.4%)
3y 4m
Median Time to Grant
Low
PTA Risk
Based on 71 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month